(Q53207213)

English

Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma.

scientific article published in November 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/18853418

Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. (English)

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/18853418

1 reference

based on heuristic

inferred from title

author name string

John P Leonard

1

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/18853418

Stephen J Schuster

2

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/18853418

Christos Emmanouilides

3

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/18853418

Felix Couture

4

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/18853418

Nick Teoh

5

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/18853418

William A Wegener

6

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/18853418

Morton Coleman

7

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/18853418

David M Goldenberg

8

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/18853418

language of work or name

0 references

publication date

1 November 2008

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/18853418

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/18853418

113

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/18853418

2714-2723

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/18853418

10

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/18853418

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23890

7 January 2021

based on heuristic

inferred from DOI database lookup

CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23890

7 January 2021

based on heuristic

inferred from DOI database lookup

Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23890

7 January 2021

based on heuristic

inferred from DOI database lookup

Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23890

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23890

7 January 2021

based on heuristic

inferred from DOI database lookup

Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23890

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23890

7 January 2021

based on heuristic

inferred from DOI database lookup

Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23890

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23890

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23890

7 January 2021

based on heuristic

inferred from DOI database lookup

Follicular lymphoma international prognostic index.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23890

7 January 2021

based on heuristic

inferred from DOI database lookup

Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23890

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23890

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematologic malignancies: new developments and future treatments

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23890

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23890

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23890

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23890

7 January 2021

based on heuristic

inferred from DOI database lookup

Re-treatment of relapsed indolent B-cell lymphoma with rituximab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23890

7 January 2021

based on heuristic

inferred from DOI database lookup

A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23890

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.23890

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/18853418

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/18853418

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53207213&oldid=1561085636"